Wire · operational-macro
Woman battling Stage 4 cancer gets access to revolutionary drug
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 26 October 2026 · Fusion42 review
A patient with Stage 4 lung cancer in Illinois received FDA approval within two days for an investigational drug targeting the DLL3 biomarker, leading to significant tumour reduction. This case showcases the FDA's Expanded Access program enabling rapid treatment options for terminal patients outside clinical trials.
This Wire brief sits within Fusion42's coverage of Healthtech Infrastructure.
◆ ◆ The Wire takeaway
You have a new opportunity to speed patients onto innovative treatments by navigating the FDA's expanded access program quickly. Early engagement with drug makers and clinical researchers is now a critical path to provide cutting-edge drugs to desperate patients.
◆ Coverage
1 source · 26 Oct 2026
◆ Related on Wire
◆ Topics